The trial will happen in 525 topics at varied websites, together with AIIMS Delhi, AIIMS Patna and Meditrina Institute of Medical Sciences, Nagpur.
The Subject Expert Committee (SEC) on Covid-19 of the Central Drugs Standard Control Organization (CDSCO) on Tuesday deliberated upon Hyderabad-based Bharat Biotech’s software searching for permission to conduct section II/III scientific trials to judge the protection, reactogenicity and immunogenicity of Covaxin jabs in youngsters aged 2 to 18 years.
“After detailed deliberation, the committee advisable for conduct of proposed section II/III scientific trial of complete virion inactivated coronavirus vaccine within the 2 to 18 years age group topic to the situation that the agency ought to submit the interim security information of section II scientific trial together with DSMB suggestions to the CDSCO earlier than continuing to section III a part of the research,” a supply stated.
Earlier the proposal was deliberated within the SEC assembly dated February 24 and the agency was requested to submit a revised scientific trial protocol.
Covaxin, indigenously developed by Bharat Biotech in collaboration with the Indian Council of Medical Analysis (ICMR), is being utilized in adults in India’s ongoing Covid-19 vaccination drive.